- Home
- ADAP vs APLT Comparison
ADAP vs APLT Comparison
Compare ADAP & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAP
- APLT
- Stock Information
- Founded
- ADAP 2008
- APLT 2016
- Country
- ADAP United Kingdom
- APLT United States
- Employees
- ADAP N/A
- APLT N/A
- Industry
- ADAP Biotechnology: Pharmaceutical Preparations
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- ADAP Health Care
- APLT Health Care
- Exchange
- ADAP Nasdaq
- APLT Nasdaq
- Market Cap
- ADAP 158.6M
- APLT 128.0M
- IPO Year
- ADAP 2015
- APLT 2019
- Fundamental
- Price
- ADAP $0.58
- APLT $0.65
- Analyst Decision
- ADAP Strong Buy
- APLT Buy
- Analyst Count
- ADAP 4
- APLT 7
- Target Price
- ADAP $2.79
- APLT $6.10
- AVG Volume (30 Days)
- ADAP 2.3M
- APLT 7.5M
- Earning Date
- ADAP 03-05-2025
- APLT 03-05-2025
- Dividend Yield
- ADAP N/A
- APLT N/A
- EPS Growth
- ADAP N/A
- APLT N/A
- EPS
- ADAP N/A
- APLT N/A
- Revenue
- ADAP $175,041,000.00
- APLT N/A
- Revenue This Year
- ADAP $204.91
- APLT N/A
- Revenue Next Year
- ADAP N/A
- APLT $2,622.90
- P/E Ratio
- ADAP N/A
- APLT N/A
- Revenue Growth
- ADAP 146.27
- APLT N/A
- 52 Week Low
- ADAP $0.53
- APLT $0.60
- 52 Week High
- ADAP $2.05
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- ADAP 41.87
- APLT 20.60
- Support Level
- ADAP $0.55
- APLT $0.60
- Resistance Level
- ADAP $0.65
- APLT $0.74
- Average True Range (ATR)
- ADAP 0.05
- APLT 0.09
- MACD
- ADAP 0.00
- APLT 0.21
- Stochastic Oscillator
- ADAP 31.31
- APLT 13.53
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.